Nothing Special   »   [go: up one dir, main page]

AU2001276737A1 - Protein injection preparations - Google Patents

Protein injection preparations

Info

Publication number
AU2001276737A1
AU2001276737A1 AU2001276737A AU7673701A AU2001276737A1 AU 2001276737 A1 AU2001276737 A1 AU 2001276737A1 AU 2001276737 A AU2001276737 A AU 2001276737A AU 7673701 A AU7673701 A AU 7673701A AU 2001276737 A1 AU2001276737 A1 AU 2001276737A1
Authority
AU
Australia
Prior art keywords
injection preparations
protein injection
protein
preparations
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276737A
Inventor
Yoshimitsu Iida
Masahiko Tanikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001276737A1 publication Critical patent/AU2001276737A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001276737A 2000-08-04 2001-08-06 Protein injection preparations Abandoned AU2001276737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-237432 2000-08-04
JP2000237432 2000-08-04
PCT/JP2001/006739 WO2002011753A1 (en) 2000-08-04 2001-08-06 Protein injection preparations

Publications (1)

Publication Number Publication Date
AU2001276737A1 true AU2001276737A1 (en) 2002-02-18

Family

ID=18729296

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276737A Abandoned AU2001276737A1 (en) 2000-08-04 2001-08-06 Protein injection preparations

Country Status (5)

Country Link
US (1) US20040038878A1 (en)
EP (1) EP1336410A4 (en)
JP (1) JP5490972B2 (en)
AU (1) AU2001276737A1 (en)
WO (1) WO2002011753A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341074A1 (en) 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
DE60109625T3 (en) † 2000-05-15 2017-08-03 F. Hoffmann-La Roche Ag LIQUID MEDICINE PREPARATION CONTAINING AN ERYTHROPOIETIN DERIVATIVE
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
CA2600608A1 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
EP1997505A4 (en) * 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
CL2007002880A1 (en) * 2006-10-06 2008-05-09 Amgen Inc STABLE FORMULATION THAT INCLUDES AN ACETIC ACID STAMP, A GLUTAMIC ACID STAMP OR A SUCCINIC ACID STAMP WITH A PH OF 4.5 TO 7, AT LEAST A EXCIPIENT THAT INCLUDES A SUGAR OR A POLYOL, AND AN ANTI-RECEPTOR ANTIBODY OF FACTOR D
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
EP2142565A4 (en) 2007-03-29 2010-03-31 Abbott Lab Crystalline anti-human il-12 antibodies
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
NZ583276A (en) 2007-08-27 2012-06-29 Biogenerix Ag Liquid formulations of granulocyte colony stimulating factor and polymer conjugates
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
SG10201604258YA (en) * 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
WO2010089522A1 (en) * 2009-07-16 2010-08-12 Arecor Limited Stable formulation of a therapeutic protein
KR101953494B1 (en) 2008-10-21 2019-02-28 박스알타 인코퍼레이티드 Lyophilized recombinant vwf formulations
JP5554244B2 (en) * 2008-11-04 2014-07-23 あすか製薬株式会社 Aqueous composition containing follicle stimulating hormone
NZ606283A (en) * 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN107693791B (en) 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 Compositions comprising stable antibodies
DK2542257T3 (en) 2010-03-01 2017-10-16 Bayer Healthcare Llc OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI)
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
MX344727B (en) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd IMPROVED HIGH CONCENTRATION ANTI-TNFa ANTIBODY LIQUID FORMULATIONS.
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP3701968A1 (en) 2012-09-07 2020-09-02 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (en) 2013-09-27 2016-04-13 Intervet Int Bv DRY FORMULATIONS OF VACCINES THAT ARE STABLE AT ENVIRONMENTAL TEMPERATURE
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN113521016A (en) 2013-11-21 2021-10-22 根马布股份公司 Antibody-drug conjugate lyophilized formulation
TW201609145A (en) * 2013-12-25 2016-03-16 參天製藥股份有限公司 Injectable agent and depot formation method
AR099470A1 (en) 2014-02-17 2016-07-27 Intervet Int Bv LIQUID CORRAL BIRD VIRUS VACCINES
TWI670085B (en) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 Swine virus vaccines that are liquid stable
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CN109496149B (en) 2016-01-13 2022-10-14 根马布股份公司 Formulation of antibodies and drug conjugates thereof
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
EA201990998A1 (en) 2016-10-21 2019-11-29 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING THEM

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920647B2 (en) * 1976-10-01 1984-05-15 武田薬品工業株式会社 injection
JP2648301B2 (en) 1983-12-27 1997-08-27 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド Vector containing auxiliary DNA for transformation of eukaryotic cells
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
JPH0565233A (en) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc Monoclonal antibody-containing lyophilized preparation
JPH0710753A (en) * 1993-06-25 1995-01-13 Taisho Pharmaceut Co Ltd Injection preparation
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
ATE209930T1 (en) * 1995-03-21 2001-12-15 Applied Research Systems LIQUID HCG FORMULATIONS
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
JPH08333277A (en) * 1995-06-05 1996-12-17 Hoechst Japan Ltd Stabilized aqueous solution formulation of human blood coagulating xiii-th factor
JPH09241178A (en) * 1996-03-07 1997-09-16 Takeda Chem Ind Ltd Production of sustained release pharmaceutical preparation of adenocorticotropic hormone derivative
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
JP3723857B2 (en) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 Aqueous pharmaceutical composition containing human growth hormone
KR100389726B1 (en) * 1998-03-06 2003-06-27 쥬가이 세이야쿠 가부시키가이샤 A stable granulocyte colony-stimulating factor-containing formulation

Also Published As

Publication number Publication date
US20040038878A1 (en) 2004-02-26
EP1336410A4 (en) 2005-10-12
WO2002011753A1 (en) 2002-02-14
JP5490972B2 (en) 2014-05-14
EP1336410A1 (en) 2003-08-20

Similar Documents

Publication Publication Date Title
AU2001276737A1 (en) Protein injection preparations
AU2001232799A1 (en) Protein c derivatives
AU2001236005A1 (en) Preparations stabilized over long time
AU2001294192A1 (en) Solid preparations
AU2001277781A1 (en) Stabilized antibody-containing preparations
AU2001273164A1 (en) Membrane associated protein zupari
AU6045900A (en) Interaction-activated proteins
AU2001282607A1 (en) Solution preparations stabilized over long time
AU2001234893A1 (en) Protein mapping
AU2001242479A1 (en) Proliposomal encapsulated preparations
AU2001286721A1 (en) Human interleukin-four induced protein
AU2001259450A1 (en) Cytoskeleton-associated proteins
AU2001288102A1 (en) Solid preparations
AU2001282521A1 (en) OCT preparations
AU2001272427A1 (en) Solid preparations
AU2001244863A1 (en) Apoptin-associating protein
AU2001274676A1 (en) Plant-signalling ligand like proteins
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001250585A1 (en) Insecticidal peptides and methods for using same
AU3506800A (en) Leukocyte- and blood-associated proteins
AU2002243234A1 (en) Embryogenesis associated proteins
AU1540701A (en) Novel protein
AU2001278777A1 (en) Irap-binding protein
AU2001278975A1 (en) Alpha-conotoxin peptides
AU2002240889A1 (en) Proteins that interact with betatrcp